Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
annamycin
- Development stage
- Phase 2
- Lead developer
- Moleculin Biotech
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Annamycin is a next-generation anthracycline antibiotic and potent topoisomerase II inhibitor being developed primarily for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma. Unlike traditional anthracyclines such as doxorubicin, annamycin is formulated to avoid dose-limiting cardiotoxicity, allowing for higher cumulative dosing without the risk of heart damage. Its mechanism involves intercalation into DNA and inhibition of topoisomerase II by stabilizing the DNA-topoisomerase II complex, leading to double-strand DNA breaks and cell death. Annamycin has demonstrated strong efficacy in drug-resistant cancer cell lines and shows synergistic activity with various FDA-approved anticancer agents across both hematologic malignancies (like AML) and solid tumors (such as sarcomas and pancreatic cancer). The drug is being evaluated in pivotal clinical trials including combination regimens with cytarabine for AML[1][2][3][5][6].
- Other names
- liposomal annamycinL-annamycin
02
Targets
TOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)
Beyond the preview
Go deeper on annamycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on annamycin.